Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is funded by PER®.

Updates in CAR T Therapy for Multiple Myeloma

Release Date: July 8, 2020
Expiration Date: July 8, 2021

Activity Overview

This continuing medical education (CME) activity is designed to inform health care providers who care for patients with multiple myeloma (MM) of the opportunities and challenges in the development of chimeric antigen receptor (CAR)-modified T-cell therapies for the treatment of patients with MM. The in-depth program will cover the key emerging CAR-T therapies undergoing evaluation for the treatment of MM, pharmacological characteristics of CAR-T therapies, and the potential place in therapy for these agents.

Acknowledgment of Support

This activity is funded by PER®.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Analyze the mechanistic properties of CAR T-cell therapies, including design characteristics that impact efficacy and safety
  • Evaluate clinical trial data regarding applications of CAR T-cell therapy in multiple myeloma management
  • Summarize the role of CAR T-cell therapy in multiple myeloma across existing indications and potential future indications

This activity was written by PER® editorial staff under faculty guidance and review. The Q&A portion of the activity was transcribed from a recorded interview with the faculty and edited by faculty and PER® editorial staff for clarity.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Sagar Lonial, MD, FACP
Sagar Lonial, MD, FACP
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family
Chair in Cancer
Chief Medical Officer
Winship Cancer Institute of Emory University
Emory School of Medicine
Atlanta, GA

Disclosures: Grant/Research Support: Janssen Pharmaceuticals, Inc, Celgene Corporation, Takeda Pharmaceutical Company Limited. Consultant: Amgen Inc, Takeda Pharmaceutical Company Limited, Celgene Corporation, Novartis AG, Bristol Myers Squibb Company, Janssen Pharmaceuticals Inc, AbbVie Inc, GlaxoSmithKline plc. Stock/ Shareholder: TG Therapeutics. Other: Board of Directors TG Therapeutics.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By